LURASIDONE IN THE LONG‐TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24‐WEEK OPEN‐LABEL EXTENSION STUDY
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The aim of this study was to evaluate the safety and tolerability of 6 months of open-label, uncontrolled extension treatment with lurasidone in patients with a diagnosis of bipolar depression who completed 6 weeks of acute treatment. METHODS: Patients completing 6 weeks of double-blind placebo-controlled treatment with either lurasidone monotherapy (one study) or adjunctive therapy with lithium or valproate (two studies), were treated for 6 months with flexible doses of lurasidone, 20-120 mg/day, in an open-label, uncontrolled extension study (N = 813; monotherapy, 38.9%; adjunctive therapy, 61.1%). Changes in safety parameters were calculated from double-blind, acute-phase baseline to month 6 of the extension phase, using a last observation carried forward (LOCF endpoint) analysis. RESULTS: Five hundred fifty-nine of 817 (68.4%) patients completed the extension study. In the monotherapy and adjunctive therapy groups, 6.9 and 9.0%, respectively, discontinued due to an adverse event. For the monotherapy and adjunctive therapy groups, respectively, changes from double-blind baseline to month 6 were +0.8 and +0.9 kg for weight (mean), 0.0 and +2.0 mg/dL for total cholesterol (median), +5.0 and +5.0 mg/dL for triglycerides (median), -1.0 and 0.0 mg/dL for glucose (median); -22.6 and -21.7 for Montgomery-Asberg Depression Rating Scale (MADRS; mean); whereas change from open-label baseline to month 6 were +0.85 and +0.88 kg for weight (mean), and -6.9 and -6.5 for MADRS (mean). CONCLUSIONS: Six months of treatment with open-label lurasidone was safe and well tolerated with minimal effect on weight and metabolic parameters; continued improvement in depressive symptoms was observed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 1×
“Suicidal ideation and behavior were assessed using the Columbia Suicide Severity Rating Scale (C-SSRS).[31]”
MethodMerikangas, K. R., Akiskal, H. S., Angst, J., Greenberg, P. E., Hirschfeld, R. M. A., Petukhova, M., & Kessler, R. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.5.543 · Cited by 2,399
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908
Self-citationCalabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883 · cited 1×
“[10] Among atypical antipsychotics, quetiapine monotherapy,[11, 12] and olanzapine in combination with fluoxetine (OFC),[13] have demonstrated efficacy in the acute treatment of bipolar depression, whereas aripiprazole monotherapy,[14] and ziprasidone monotherapy[15] and adjunctive therapy (with lithium or divalproex)…”
BackgroundSelf-citationThase, M. E., Macfadden, W., Weisler, R. H., Chang, W., Paulsson, B., Khan, A., & Calabrese, J. R. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000248603.76231.b7 · Cited by 559 · cited 1×
“[10] Among atypical antipsychotics, quetiapine monotherapy,[11, 12] and olanzapine in combination with fluoxetine (OFC),[13] have demonstrated efficacy in the acute treatment of bipolar depression, whereas aripiprazole monotherapy,[14] and ziprasidone monotherapy[15] and adjunctive therapy (with lithium or divalproex)…”
BackgroundGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & WFSBP Task Force On Treatment Guidelines For Bipolar Disorders (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903555881 · Cited by 399
Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder 1
Kupka, R. W., Altshuler, L. L., Nolen, W. A., Suppes, T., Luckenbaugh, D. A., Leverich, G. S., Frye, M. A., Keck, P. E., McElroy, S. L., Grunze, H., et al. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00467.x · Cited by 397 · cited 1×
“The treatment of recurrent depressive episodes, which predominate over manic episodes in the majority of patients,[2, 3] is an unmet need in the long-term treatment of bipolar disorder.”
BackgroundMüller, M. (2003) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00120-9 · Cited by 282
Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States
Goldstein, B. I., Fagiolini, A., Houck, P., & Kupfer, D. J. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00735.x · Cited by 259 · cited 1×
“There is an increased risk of metabolic syndrome and cardiovascular disease in the bipolar disorder population.[43, 44] The relatively benign cardiometabolic risk profile of lurasidone may make it a potentially safer treatment option in this vulnerable clinical population.”
BackgroundThase, M. E., Jonas, A., Khan, A., Bowden, C. L., Wu, X., McQuade, R. D., Carson, W. H., Marcus, R. N., & Owen, R. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181618eb4 · Cited by 251 · cited 1×
“[10] Among atypical antipsychotics, quetiapine monotherapy,[11, 12] and olanzapine in combination with fluoxetine (OFC),[13] have demonstrated efficacy in the acute treatment of bipolar depression, whereas aripiprazole monotherapy,[14] and ziprasidone monotherapy[15] and adjunctive therapy (with lithium or divalproex)…”
BackgroundVieta, E., Suppes, T., Eggens, I., Persson, I., Paulsson, B., & Brecher, M. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.06.001 · Cited by 227
Sachs, G. S., Ice, K. S., Chappell, P. B., Schwartz, J. H., Gurtovaya, O., Vanderburg, D. G., & Kasuba, B. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05934 · Cited by 101
Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression
Brown, E., Dunner, D. L., McElroy, S. L., Keck, P. E., Adams, D. H., Degenhardt, E., Tohen, M., & Houston, J. P. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009735 · Cited by 73 · cited 1×
“Limited data suggest that OFC might be effective as a long-term therapy for prevention of depressive relapse,[21, 22] although weight gain and metabolic effects may limit the utility of this treatment.”
BackgroundVieta, E., Suppes, T., Ekholm, B., Udd, M., & Gustafsson, U. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.04.014 · Cited by 37
Cited by
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Azorin, J.-M., Yatham, L., Mosolov, S., Möller, H.-J., Kasper, S., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1384850 · Cited by 187
“Patients who completed the controlled acute treatment trials were also eligible for a 6-month open-label extension study (Ketter et al. 2016), which was then prolonged for an additional 18 months of continuation treatment with flexible, once-daily doses of lurasidone in the range of 20–80mg…”
DelBello, M. P., Goldman, R., Phillips, D., Deng, L., Cucchiaro, J., & Loebel, A. (2017) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2017.10.006 · Cited by 135
Self-citationCalabrese, J. R., Pikalov, A., Streicher, C., Cucchiaro, J., Mao, Y., & Loebel, A. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.06.013 · Cited by 55
Self-citationKato, T., Ishigooka, J., Miyajima, M., Watabe, K., Fujimori, T., Masuda, T., Higuchi, T., & Vieta, E. (2020) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13137 · Cited by 49
“Previous studies indicate that long-term treatment with lurasidone in bipolar depression is associated with a low risk of triggering a manic switch; and in one double-blind maintenance trial in bipolar depression, lurasidone was associated with a 43% reduction in the risk of developing mania versus placebo (both treat…”
Background
Metadata
- Authors
- Ketter, T. A., Sarma, K., Silva, R., Kroger, H., Cucchiaro, J., & Loebel, A.
- Venue
- Depression and Anxiety
- Publisher
- Wiley
- Published
- 2016-02-26
- Volume
- 33
- Issue
- 5
- Pages
- 424-434
- ISSN
- 1091-4269 (ISSN-L)
- 1520-6394
- OpenAlex
- W2287944760
- Cited by
- 69
- References
- 15
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.